BRPI0407303A - Composição farmacêutica - Google Patents

Composição farmacêutica

Info

Publication number
BRPI0407303A
BRPI0407303A BR0407303-7A BRPI0407303A BRPI0407303A BR PI0407303 A BRPI0407303 A BR PI0407303A BR PI0407303 A BRPI0407303 A BR PI0407303A BR PI0407303 A BRPI0407303 A BR PI0407303A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
hyperinsulinemia
preventative
remedy
analogues
Prior art date
Application number
BR0407303-7A
Other languages
English (en)
Inventor
Takao Ikenoue
Yoko Kageyama
Yukio Iino
Nobuo Kondo
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of BRPI0407303A publication Critical patent/BRPI0407303A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA". Um preventivo e/ou remédio para a diabete, complicações diabéticas, hiperinsulinemia, erro metabólico do açúcar ou obesidade caracterizados por compreender uma combinação de um composto representado pela seguinte fórmula, seus análogos ou um sal destes farmaceuticamente aceitáveis com um agente hipoglicêmico.
BR0407303-7A 2003-02-07 2004-02-06 Composição farmacêutica BRPI0407303A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003031088 2003-02-07
PCT/JP2004/001279 WO2004069259A1 (ja) 2003-02-07 2004-02-06 糖尿病治療剤

Publications (1)

Publication Number Publication Date
BRPI0407303A true BRPI0407303A (pt) 2006-02-07

Family

ID=32844288

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407303-7A BRPI0407303A (pt) 2003-02-07 2004-02-06 Composição farmacêutica

Country Status (11)

Country Link
US (1) US7807663B2 (pt)
EP (1) EP1595544A4 (pt)
JP (1) JPWO2004069259A1 (pt)
KR (1) KR20050097537A (pt)
CN (2) CN101822834A (pt)
AU (1) AU2004210268B8 (pt)
BR (1) BRPI0407303A (pt)
CA (1) CA2515294A1 (pt)
MX (1) MXPA05008363A (pt)
RU (1) RU2358738C2 (pt)
WO (1) WO2004069259A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI241302B (en) * 2000-12-01 2005-10-11 Ajinomoto Kk Lactam compounds and pharmaceutical use thereof
AU2004261353B2 (en) 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
WO2005042536A1 (ja) * 2003-10-31 2005-05-12 Ajinomoto Co., Inc. 複素環を有する新規縮合多環式化合物及びその医薬用途
CA2553329A1 (en) * 2004-01-14 2005-07-28 Ajinomoto Co., Inc. New fused polycyclic compounds
JP5056412B2 (ja) 2005-04-28 2012-10-24 味の素株式会社 新規ラクタム化合物
WO2006119038A1 (en) * 2005-04-29 2006-11-09 Naturegen, Inc. Compositions and methods for controlling glucose uptake
WO2007019526A2 (en) * 2005-08-05 2007-02-15 Naturegen, Inc. Compositions and methods for controlling glucose and lipid uptake from foods
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
EP2157092A4 (en) * 2007-04-11 2011-04-13 Ajinomoto Kk Remedy for diabetes
WO2008139575A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. 経口投与用製剤
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008136394A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の製造方法及びその製造中間体
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
CN102202683A (zh) 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
KR101904920B1 (ko) * 2012-05-18 2018-10-08 (주)아모레퍼시픽 보글리보스를 포함하는 피부 미백용 조성물
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2961377A (en) * 1957-08-05 1960-11-22 Us Vitamin Pharm Corp Oral anti-diabetic compositions and methods
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
NL132376C (pt) * 1966-02-10
US4062950A (en) * 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
FR2774591B1 (fr) * 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
US20020099186A1 (en) * 2000-11-29 2002-07-25 Synsorb Biotech, Inc. Processes for the preparation of alphaGal(1-3)betaGal(1-4)Glc-OR
TWI241302B (en) * 2000-12-01 2005-10-11 Ajinomoto Kk Lactam compounds and pharmaceutical use thereof
WO2005042536A1 (ja) 2003-10-31 2005-05-12 Ajinomoto Co., Inc. 複素環を有する新規縮合多環式化合物及びその医薬用途

Also Published As

Publication number Publication date
US7807663B2 (en) 2010-10-05
EP1595544A4 (en) 2009-05-06
RU2358738C2 (ru) 2009-06-20
CN1771040B (zh) 2010-06-16
CA2515294A1 (en) 2004-08-19
MXPA05008363A (es) 2005-12-06
CN101822834A (zh) 2010-09-08
AU2004210268A1 (en) 2004-08-19
AU2004210268B8 (en) 2009-06-04
US20050272641A1 (en) 2005-12-08
EP1595544A1 (en) 2005-11-16
KR20050097537A (ko) 2005-10-07
JPWO2004069259A1 (ja) 2006-05-25
WO2004069259A1 (ja) 2004-08-19
RU2005127870A (ru) 2006-03-10
CN1771040A (zh) 2006-05-10
AU2004210268B2 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
BRPI0615150A2 (pt) agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
BRPI0511703A (pt) composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o inìcio do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, sìndrome x, um distúrbio lipìdico, aterosclerose, e uma condição
BR0312844A (pt) Derivado 2-ciano-4-fluorpirrolidina ou seu sal
WO2007014895A3 (en) Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives
ZA200802454B (en) Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
EP1553094A4 (en) AZULATE DERIVATIVES AND THEIR SALTS
CL2006003672A1 (es) Compuestos derivados de pirimido-[4,5-b]-oxazinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes mellitus y/u obesidad.
AR032065A1 (es) Derivados de glucopiranosiloxipirazol y composicion farmaceutica
EP1595544A4 (en) MEANS FOR THE TREATMENT OF DIABETES
BR0314799A (pt) Controle glicêmico aperfeiçoado para pré-diabetes e/ou diabetes do tipo ii usando ácido docosahexaenóico
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
JP2009501177A5 (pt)
JP2009501178A5 (pt)
WO2008055940A3 (en) Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
BR0114310A (pt) Derivados do glicopiranosiloxibenzilbenzeno e composições medicinais contendo os mesmos
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
BR9809968A (pt) Aplicação de derivados tiazolidinadiona no tratamento da pcos e diabetes gestacional
AR047779A1 (es) Composiciones y metodos para tratar diabetes
BR0016135A (pt) Forma de tamanho de partìcula reduzido, uso de uma substância, composição farmacêutica, métodos para o tratamento ou a profilaxia de condições associadas com reduzida sensibilidade à insulina e de deslipidemia, diabetes melito do tipo ii, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal e processo para a preparação de um composto
BR0011928A (pt) Composto, composição farmacêutica, uso de, um composto e métodos para o tratamento de complicações diabéticas, para o tratamento ou a prevenção do desenvolvimento de condições de doença associadas com velocidade de condução neuronial prejudicada e de neuropatia diabética
MX2022013588A (es) Combinación de fármacos para tratar la diabetes mellitus y sus complicaciones y composición farmacéutica de la combinación de fármacos.
MXPA04007183A (es) Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2.
BR0317359A (pt) Uso de ácidos alfa-feniltiocarboxìlico e alfa-feniloxicarboxìlico com atividade de diminuição de glicose no soro e diminuição de lipìdios no soro
EP1550668A4 (en) PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION COMPRISING THE DERIVATIVE, MEDICINAL USE THEREOF, AND INTERMEDIATE ENTERING THE PRODUCTION THEREOF

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.